STAT+: Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug
WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want Congress to take a deeper look at how Biogen’s controversial and pricey new Alzheimer’s drug, Aduhelm, will affect the Medicare program, they wrote in a letter Wednesday.
The bipartisan duo is pressing the Senate Finance Committee to take on “ the vexing new questions and challenges that approval raises for the Medicare program and other health programs” the panel oversees, they wrote.
